Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03187990 Recruiting - Prostate Cancer Clinical Trials

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

Start date: March 3, 2017
Phase: N/A
Study type: Interventional

In 22% of patients with elevated Prostate-specific antigen (PSA) MRI guided biopsy will not detect significant prostate cancer (PCA) (defined as either: Gleason score (GS) ≥ 3+4 or tertiary pattern 5, or final stage ≥ pT3a and/or pN1). Therefore this study evaluates the ability of [68Ga]PSMA PET/MRI to detect and localize significant primary PCA to accurately direct prostate needle biopsy using the Gleason score from the histology of the core biopsies as standard of truth.

NCT ID: NCT03178383 Recruiting - Breast Cancer Clinical Trials

Integration of Cancer Health Activities Into African American Churches

Start date: July 1, 2016
Phase: N/A
Study type: Interventional

This population-based application responds to the American Cancer Society Research Scholar Grant, Priority Program in Cancer Control. Recent years have seen a growing research interest in learning how to get known-effective health education strategies to reach more people who could benefit from them. An important part of this growing movement is a focus on sustained impact, or continued program benefit after the funding period is over. It is believed that the best way to achieive this sustained impact is through integrating the program into the host community at multiple levels. This innovative strategy has not been systematically tested in community-based settings, where the most vulnerable people can be reached. Since churches have a historical and ever-growing role in health promotion particularly among African Americans, they are an ideal place to reach this group for cancer education. The proposed project will compare two ways to apply a known-effective cancer educational strategy through African American churches: 1) a standard method vs. 2) a new method in which the churches integrate the strategy into their organizational structure and practice at multiple levels. It will be determined whether this "integrated approach" results in more effective and sustained cancer education and screening activities at both the church and individual levels over time. The educational strategy is one that has been used successfully in previous work: Project HEAL (Health through Early Awareness and Learning). Project HEAL is a series of three cancer early detection workshops (breast, prostate, colorectal) delivered through trained and certified lay peer community health advisors in African American churches. 14 churches will be randomly chosen to conduct either the standard Project HEAL program or an integrated Project HEAL strategy where the churches build the program into their organization in multiple ways (e.g., allocating volunteer or paid staff, space, or funds; policy change; ministry development). The project will be conducted in three phases: 1) refining the integrated approach with community and stakeholder feedback; 2) pilot testing the integrated approach in 2 churches; and 3) conducting the study to comparatively evaluate the standard vs. the integrated approaches in 14 churches. A scientifically rigorous evaluation plan will be used to look at outcomes at both the individual and the church level. This project will make important contributions to research in evidence-based medicine and sustainability. In a climate of limited resources, identifying sustainable and effective ways to increase cancer awareness and screening in African American men and women is more important than ever.

NCT ID: NCT03177759 Recruiting - Prostate Cancer Clinical Trials

Living With Prostate Cancer (LPC)

LPC
Start date: September 9, 2016
Phase: N/A
Study type: Observational

This is a prospective evaluation to determine the effectiveness of the Prostate Cancer Supportive Care (PCSC) Program's group therapy program, Living with Prostate Cancer (LPC). LPC is an intervention which utilizes a small group format (5-7 participants with 2 leaders and a paraprofessional counselling student) to understand and learn how to manage emotional responses, depressive symptoms, and life stressors associated with prostate cancer. Data for this evaluation will be derived from a focus group (at 3 months) and self-report questionnaires that participants will complete immediately prior to the intervention, immediately following the intervention and at 3, 6, and 12-months post-intervention.

NCT ID: NCT03177707 Recruiting - Prostate Cancer Clinical Trials

Intimacy and Mindfulness Post-Prostate Cancer Treatment

IMPPACT
Start date: January 2017
Phase: N/A
Study type: Interventional

With improvements in detection and treatment of prostate cancer (PCa), more men than ever are living with side effects from PCa treatment; most distressingly, treatment side effects include problems with sexual functioning (e.g. erectile dysfunction, climacturia, inorgasmia). This study aims to develop a mindfulness-based group treatment for couples with sexual functioning complaints post-PCa treatment. Couples will be invited to a four-session mindfulness-based treatment group. Pre- and post-treatment outcomes (e.g., distress, sexual functioning/enjoyment, relationship satisfaction, treatment adherence) will assess feasibility and effectiveness of this novel treatment for couple's sexual lives after PCa.

NCT ID: NCT03177460 Recruiting - Prostate Cancer Clinical Trials

A Pilot Presurgical Study of Daratumumab in Men With High-Risk Localized Prostate Cancer

Start date: June 7, 2017
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to learn about the safety and tolerability of giving Darzalex (daratumumab) to patients who have prostate cancer before having an already-scheduled prostatectomy (surgical removal of the prostate). Researchers also want to learn if daratumumab can help to control the disease before the prostatectomy.

NCT ID: NCT03164837 Recruiting - Prostate Cancer Clinical Trials

68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients

Start date: November 2016
Phase: Phase 1
Study type: Interventional

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-RM26 in prostate cancer patients. A single dose of 111-148 Mega-Becquerel (MBq) 68Ga-NOTA-RM26 will be injected intravenously. Visual and semiquantitative method will be used to assess the PET/CT images.

NCT ID: NCT03159676 Recruiting - Prostate Cancer Clinical Trials

Proton-Based Stereotactic Ablative Body Radiotherapy for Patients With Localized Prostate Cancer

Start date: May 12, 2017
Phase: N/A
Study type: Observational

Patients will receive proton beam-based SABR as standard of care. Standard of care will include clinical examinations and testing (serum prostate-specific antigen levels, computed tomography, magnetic resonance imaging, urodynamics, bone scan, proton beam therapy dosimetry), and in follow-up monitoring of quality of life.

NCT ID: NCT03158922 Recruiting - Prostate Cancer Clinical Trials

The BARCODE 1 Study

BARCODE1Pilot
Start date: April 29, 2016
Phase: N/A
Study type: Observational

BARCODE 1 is a screening study designed to investigate the role of genetic profiling for targeting population prostate cancer screening. This study forms a pilot of 300 men, with the view to continue to a future study of 5000 men.

NCT ID: NCT03156244 Recruiting - Prostate Cancer Clinical Trials

Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients

Start date: May 8, 2017
Phase: N/A
Study type: Observational

In this pilot study, a total of 80 patients with prostate or bladder cancer (40 black, 40 white) will complete 3 patient-reported outcome (PRO) surveys: baseline (pre-treatment), during treatment, and after treatment. The overall goal of this study is to assess whether collecting patient-reported data is feasible as part of clinical care of cancer patients, and whether these data are useful for clinicians and patients. Among these 80 patients, those who agree will also undergo a semi-structured interview to assess value of HRQOL assessment at the end of the study. Of specific interest is an evaluation of whether feasibility and perceived value differ between black and white participants.

NCT ID: NCT03152448 Recruiting - Prostate Cancer Clinical Trials

Prospective Prolaris Value and Efficacy

P-PROVE
Start date: September 1, 2015
Phase: N/A
Study type: Observational [Patient Registry]

This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.